Abstract:
:One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age of 60, received a doxorubicin-containing regimen (119 had CHOP, 65 had BACOP and 47 had m-BACOD). For stage I patients, the clinical results were similar but for stage II, III or IV disease, those receiving COPP had significantly worse CR rate and survival than those who had a doxorubicin-containing regimen. Multivariate analysis on patients receiving the COPP chemotherapy revealed that the independent prognostic variables significantly determining CR rate and survival included clinical stage (p = 0.04) and serum lactate dehydrogenase level (p = 0.001). Myelosuppression was the major toxicity following COPP chemotherapy in this group of patients. There were 10 (7 per cent) treatment-related deaths. Compared to the reported results using doxorubicin-containing regimens to treat elderly patients with aggressive NHL in the literature, the more aggressive treatment does not appear to improve significantly the clinical outcome of this group of patients and seems to produce treatment results very much similar to COPP. However, accurate comparison is difficult because of the variation in the patient characteristics. Further prospective controlled randomized trials will be necessary to determine the optimal therapy for these patients.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho Fdoi
10.1002/hon.2900110106subject
Has Abstractpub_date
1993-01-01 00:00:00pages
43-50issue
1eissn
0278-0232issn
1099-1069journal_volume
11pub_type
临床试验,杂志文章abstract::The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2676
更新日期:2020-02-01 00:00:00
abstract::Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a tw...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/1099-1069(200009)18:3<111::aid-hon657>3.0.
更新日期:2000-09-01 00:00:00
abstract::The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and age (< or >60). The IPSET-thrombosis takes into account four risk factors: age greater than 60 years and the presence of CV risk factors, thrombosis history and J...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2670
更新日期:2019-10-01 00:00:00
abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.780
更新日期:2006-09-01 00:00:00
abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析,评审
doi:10.1002/hon.2152
更新日期:2015-09-01 00:00:00
abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2652
更新日期:2019-10-01 00:00:00
abstract::In the last four years we established five long term cultures from tumor material of Hodgkin's disease. The in vitro cells have malignant characteristics and represent the in vivo H- and SR-cells. Common immunological, functional and morphological assays did not characterize the in vitro cells to be a known cell type ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900010204
更新日期:1983-04-01 00:00:00
abstract::Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2647
更新日期:2019-10-01 00:00:00
abstract::Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070407
更新日期:1989-07-01 00:00:00
abstract::The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2811
更新日期:2020-09-26 00:00:00
abstract::We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900120304
更新日期:1994-05-01 00:00:00
abstract::We compare 30 biopsies each of Pattern 1 angioimmunoblastic T-cell lymphoma (AITL1) and reactive lymphoid hyperplasia (RLH) by immunohistology, in-situ hybridization for Epstein-Barr virus-encoded RNA and T-cell receptor-γ (TRG)-clonality. AITL1 cases, more often than RLH controls, were older [median ages 61 (range 23...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2116
更新日期:2014-09-01 00:00:00
abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2195
更新日期:2016-09-01 00:00:00
abstract::Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patients with initial le...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900030107
更新日期:1985-01-01 00:00:00
abstract::Smoking has been identified as a significant risk factor for acute myeloid leukaemia (AML). However, epidemiological evidence for the effect of smoking on the risk of AML among Asians is scarce. Here, we investigated the impact of smoking habits on the risk of AML by conducting a pooled analysis of 9 population-based ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2457
更新日期:2018-02-01 00:00:00
abstract::The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900020210
更新日期:1984-04-01 00:00:00
abstract::To extend the clinical-pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage II...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070506
更新日期:1989-09-01 00:00:00
abstract::Mucosa-associated lymphatic tissue (MALT) lymphoma of the breast is an extremely rare disease; its pathogenesis is not clear because of the rarity of disease, and the best diagnostic method has yet to be established. The metabolic behavior of this lymphoma is not still clear because only a few case reports are present...
journal_title:Hematological oncology
pub_type:
doi:10.1002/hon.2376
更新日期:2017-12-01 00:00:00
abstract::Sixty-five cases of malignant lymphoma of the nose, paranasal sinuses and hard palate were retrospectively analysed to identify the presence or absence of angiocentric lesions. We observed that the 23 patients with angiocentric lesions had a worse prognosis with a shorter duration of response and also a shorter durati...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900100303
更新日期:1992-05-01 00:00:00
abstract::Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析
doi:10.1002/hon.2173
更新日期:2015-12-01 00:00:00
abstract::Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2205
更新日期:2016-12-01 00:00:00
abstract::Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2178
更新日期:2016-03-01 00:00:00
abstract::Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2050
更新日期:2014-03-01 00:00:00
abstract::There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2635
更新日期:2019-08-01 00:00:00
abstract::Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/(sici)1099-1069(1998030)16:1<33::aid-hon62
更新日期:1998-03-01 00:00:00
abstract::There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析
doi:10.1002/hon.2015
更新日期:2013-03-01 00:00:00
abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2344
更新日期:2017-12-01 00:00:00
abstract::These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2454
更新日期:2018-02-01 00:00:00
abstract::Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2483
更新日期:2018-02-01 00:00:00
abstract::Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900080205
更新日期:1990-03-01 00:00:00